Integra LifeSciences Holdings Co. (NASDAQ:IART) Short Interest Update

Integra LifeSciences Holdings Co. (NASDAQ:IART) saw a significant growth in short interest in July. As of July 31st, there was short interest totalling 4,400,000 shares, a growth of 6.5% from the July 15th total of 4,130,000 shares. Approximately 6.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,650,000 shares, the short-interest ratio is presently 2.7 days.

Integra LifeSciences Stock Down 1.4 %

Integra LifeSciences stock traded down $0.30 during trading on Friday, hitting $21.56. 526,854 shares of the company were exchanged, compared to its average volume of 1,155,710. The company has a market capitalization of $1.70 billion, a P/E ratio of 43.12, a PEG ratio of 0.84 and a beta of 1.11. The business’s 50 day moving average is $27.69 and its 200 day moving average is $31.80. Integra LifeSciences has a 52 week low of $21.08 and a 52 week high of $45.42. The company has a current ratio of 3.39, a quick ratio of 3.35 and a debt-to-equity ratio of 1.17.

Integra LifeSciences (NASDAQ:IART) last announced its earnings results on Monday, July 29th. The life sciences company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.62 by $0.01. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. The company had revenue of $418.20 million during the quarter, compared to the consensus estimate of $413.07 million. During the same quarter in the prior year, the company posted $0.71 earnings per share. The firm’s revenue for the quarter was up 9.7% on a year-over-year basis. Analysts predict that Integra LifeSciences will post 2.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on IART shares. Citigroup lowered Integra LifeSciences from a “neutral” rating to a “sell” rating and lowered their target price for the stock from $30.00 to $23.00 in a research report on Tuesday, July 30th. Bank of America reduced their target price on Integra LifeSciences from $42.00 to $26.00 and set an “underperform” rating on the stock in a report on Tuesday, May 7th. JMP Securities lowered their target price on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a research note on Tuesday, July 30th. Wells Fargo & Company downgraded Integra LifeSciences from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $45.00 to $25.00 in a report on Tuesday, May 7th. Finally, BTIG Research cut Integra LifeSciences from a “neutral” rating to a “sell” rating and set a $22.00 price target on the stock. in a report on Tuesday, July 30th. Four investment analysts have rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, Integra LifeSciences presently has an average rating of “Hold” and an average target price of $29.25.

Insider Transactions at Integra LifeSciences

In other news, Chairman Stuart Essig purchased 52,641 shares of Integra LifeSciences stock in a transaction dated Thursday, May 23rd. The shares were bought at an average cost of $28.49 per share, for a total transaction of $1,499,742.09. Following the completion of the acquisition, the chairman now owns 487,922 shares in the company, valued at approximately $13,900,897.78. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 3.10% of the company’s stock.

Institutional Trading of Integra LifeSciences

A number of institutional investors and hedge funds have recently modified their holdings of the business. Signaturefd LLC grew its stake in Integra LifeSciences by 248.5% in the 4th quarter. Signaturefd LLC now owns 582 shares of the life sciences company’s stock valued at $25,000 after purchasing an additional 415 shares during the period. Blue Trust Inc. increased its holdings in Integra LifeSciences by 100.5% during the second quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock worth $26,000 after buying an additional 444 shares during the last quarter. Hexagon Capital Partners LLC raised its position in Integra LifeSciences by 123.3% in the fourth quarter. Hexagon Capital Partners LLC now owns 670 shares of the life sciences company’s stock worth $29,000 after acquiring an additional 370 shares during the period. CWM LLC boosted its stake in Integra LifeSciences by 50.8% in the second quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock valued at $37,000 after acquiring an additional 425 shares during the last quarter. Finally, Valley National Advisers Inc. bought a new position in shares of Integra LifeSciences during the 1st quarter valued at approximately $63,000. 84.78% of the stock is owned by hedge funds and other institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.